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Characterization of exosomes from glioma cells under hypoxia 
and oxidative stress 
Katarina Tomazin 
Exosomes are cell-secreted nanosized (30-
200 nm) membrane vesicles that contain 
cytosol proteins and nucleic acids (mRNA, 
miRNA and mDNA). They have been 
characterized to be released by most cell 
types and thus, represent an important 
part of cell-cell communication. Especially 
they might play an important role in cell 
adaptation processes to stress conditions 
such as hypoxia or oxidative stress. The 
main difficulty in studying exosomes is 
however their purification and 
characterization process which is still a 
major challenge in the field of exosome 
research. In this study, we set up the 
method for isolation of exosomes with 
differential centrifugation and two 
characterization techniques nanoparticle 
tracking analysis (NTA) and bicinchoninic 
acid assay (BCA). With the latter 
techniques we studied whether glioma 
cells exposed to stress conditions produce 
more exosomes as communication 
messengers compared to standard 
environment. The study so far did not 
answer this question, our data 
nevertheless show the initial evidence that 
exosomes reflect the inner metabolic 
status of cells. 
____________________________________ 
Introduction 
Exosomes and their importance 
Cells are basic structural units of all living 
organisms. In order to form functional 
multicellular living systems, communication 
is vital. Traditionally it was believed that this 
intercellular communication depended only 
on physical contact between cell membranes 
and by free diffusion of small cell-secreted 
soluble molecules such as neurotransmitters, 
hormones and cytokine (1). In the past three 
decades, it has been revealed that, in 
addition, a big portion of the cell-cell 
communication is relayed by membrane 
vesicle trafficking (2, 3). The discovery of 
molecular mechanisms that drive the 
delivery of membrane vesicles and their 
cargo to the right target at the right time was 
recently awarded by the 2013 Nobel Prize in 
Physiology or Medicine, highlighting the 
importance of this cell process (4). These 
cell-secreted lipid vesicles can be 
categorized into three types, depending on 
how they are formed. Apoptotic bodies are 
released during apoptosis, process of 
programmed cell death, varying in size from 
500 -2000 nm, whereas microvesicles and 
exosomes are extracellular vesicles released 
form healthy cells. The former are produced 
by outward budding of the cell membrane 
which releases vesicles with a size varying 
from 50 -1000 nm (3). These have been 
observed to be largely involved in, for 
example, tumor progression and 
inflammation (5, 6). Exosomes, studied in 
this paper, are instead formed inside the cells 
as a part of the endosomal pathway. Briefly, 
primary endocytic vesicles are generated by 
endocytosis and are later fused with the 
plasma membrane into an early endosome 
that matures to a late endosome or a so-
called multivesicular body (MVB). 
Exosomes get loaded during that process 
with various types of proteins (e.g. derived 
from the Golgi complex (GC), 
endoplasmatic reticulum (ER), cytoplasm 
and lipid rafts) and genetic material from 
cytoplasm. Eventually the MVB fuses with 
the plasma membrane, resulting in the 
secretion of exosomes to the extracellular 
space (Figure 1) (7, 8). Due to their 
biogenesis, exosomes are generally 
considered to be smaller than other 
microvesicles with size varying between 30-
200 nm in diameter (3, 9, 10). The estimate 
of exosome size range differs from one 
report to another since the different isolation 
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and characterization techniques may result in 
different size distributions as described 
below.  
 
Cell-released vesicles were described for the 
first time in 1983 by Pan et al. where they 
were observed to be secreted by the 
reticulocytes into the extracellular space, 
carrying transferrine receptor on their surface 
(2). Four years later these vesicles were 
termed  ‘exosomes’ and were characterized 
as particles that discarded unnecessary 
proteins from the reticulocytes during their 
maturation (11).  For many years they were 
thought to be a cellular disposing machinery 
of cell debris and unneeded membrane 
proteins (12).  Subsequent research led to the 
discovery that exosomes were involved in 
much more complex functions, such as 
antigen presentation, immune suppression 
and tumor invasiveness (8, 12, 13). These 
discoveries have led to an increased interest 
in the exosome research field that drastically 
expanded since then (12).   
The structure of the exosome was shown to 
consist of a lipid bilayer membrane with the 
presence of membrane proteins (8). This 
membrane is encapsulating an aqueous core 
of soluble proteins and genetic material (8, 
14). The composition of their cargo may 
differ depending on the cell of origin but 
generally exosomes carry in their membranes 
specific subclasses of proteins, reflecting 
their intracellular site of origin, which can be 
used as exosomal markers (8, 15). These 
specific subclasses include mainly 
tetraspanins (e.g. CD9, CD63 and CD81), 
but also cytoplasmic proteins (e.g. actin, 
annexins, Rab proteins) and heat shock 
proteins (e.g. Hsc70, Hsp90) (8, 12). Genetic 
material inside the exosomal core is 
composed of messenger RNA (mRNA), 
small non-coding micro RNA (miRNA) and 
mitochondrial DNA (mtDNA) that can be 
transported to recipient cells (Figure 2) (14, 
16). When transferred to a recipient cell, 
exosomal mRNA can be translated into 
proteins (14) and miRNA can modulate the 
gene expression (17).  
Packaging of exosomal content inside the 
cell was shown not to be random but rather 
selective. Several reports have demonstrated 
that specific mRNAs, miRNAs and proteins 
are enriched in exosomes of the donor cell 
through yet unknown selective mechanisms 
(9, 14). The selective packaging can thus 
depend on different conditions the donor cell 
is in (e.g. natural, hypoxia, oxidative stress) 
or on the differential availability of material 
in the cell due to changed extracellular 
conditions (18, 19). Following secretion of 
exosomes to the extracellular space, they can 
interact with other cells and induce various 
physiological changes (12). These 
mechanisms of interactions have not been 
completely understood but studies suggested 
that exosomes can interact with the recipient 
cells in multiple ways. Fusion of the lipid 
bilayer-surrounded exosome with the 
recipient plasma cell membrane results in the 
release of the exosomal content into the 
recipient cell (9). Other proposed 
mechanisms are that exosomes can bind to a 
specific receptor expressed on the target cell 
which facilitates the uptake (20) or 
endocytosis followed by the fusion of 
exosomes into the endosomal pathway (21).  
Figure 1: Biogenesis of exosomes. Exosomes are 
generated in the MVBs, late endosomal 
compartments, in the endosomal pathway inside the 
cell.  They can carry various types of proteins derived 
from the GC, ER (in this case rough ER, RER), 
cytoplasm and lipid rafts that are directly sorted in the 
MVBs together with the mRNA, microRNA and 
mDNA from the cytoplasm. Exosomes are released to 
the extracellular space with the fusion of MVBs with 
the plasma membrane, or so-called exocytosis (10). 
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Since the exosomes were first discovered, 
several studies have demonstrated that a 
wide range of cell types have the ability to 
generate exosomes, including tumor cells, 
dendritic cells, B cells, T cells, epithelial 
cells, mast cells, platelets, cells in neuron 
system  and stem cells (12, 14, 15, 22).  
Moreover, most cells in the nervous system, 
such as neural stem/progenitor cells, 
neurons, astrocytes, microglia, and 
oligodendrocytes, have the capability to 
release exosomes (23-26). Exosomes, 
released from different cell types, can cause 
a variety of physiological and pathological 
changes to the recipient cell, depending on 
the cell of origin and the secretion conditions 
(12, 15). For example, mast cells can secrete 
exosomes that promote activation of B and T 
lymphocytes and hence trigger immune 
responses (27). It is also well studied that 
various types of tumor cells (e.g. breast, 
brain and lung) produce high amounts of 
exosomes, correlating with the stage of 
malignancy. These have the ability to 
manipulate the tumor microenvironment 
therefore promoting tumor growth and 
invasion (15). For example, glioblastoma-
derived exosomes were shown to activate 
angiogenic response by endothelial cells (9). 
What is more, due to the stability of the 
exosomes, they can travel to distant parts of 
the body through body fluids and possibly 
alter the endothelium, contributing to the 
larger metastatic potential of a tumor (28).  
Exosomes have been found to be present in 
body fluids, including human plasma, serum, 
urine, breast milk and bronchoalveolar fluid 
of healthy individuals (29). In some diseases 
(e.g. cancer) can their amounts in serum 
drastically increase and exosomes might 
therefore be used as diagnostic markers since 
they can display the tumor characteristics in 
surface molecules and carry tumor-
associated mRNAs and miRNAs (12). 
Furthermore, due to the ability of most cells 
to uptake exosomes there has been research 
aiming towards their use as delivery vehicles 
for therapeutic applications (30). One 
advantage of this approach is that the 
exosomes compared to other delivery 
vesicles are very stable in body fluids but 
also less immunogenic if the patient’s own 
cells are used for their production (31).  
Methodological considerations 
The process of isolating and characterizing 
exosomes is still a debated topic and a major 
challenge in the field of exosome research 
since they are mixed with the other 
membrane vesicles in the extracellular 
environment. Generally exosomes are 
collected from the body fluids or from the 
supernatant of cultured cells grown in the 
defined medium or medium with fetal bovine 
serum that has prior been depleted of 
exosomes (32). These samples need to be 
later purified by multiple centrifugation 
steps. First of all, low g-force centrifugation 
(500 – 1000 x g) is used to remove the cells 
and bulky cell debris followed by higher g-
force centrifugation (16000 – 20000 x g) to 
remove apoptotic bodies and microvesicles 
(14, 32, 33). Finally, the exosomes 
containing pellet is obtained by 
ultracentrifugation at a very high g-force 
(100000 – 120000 x g) (14). The major 
drawback of differential ultracentrifugation 
protocols is that co-sedimentation can occur 
due to overlapping density of protein 
aggregates or large microvesicles together 
with exosomes, which makes the sample less 
pure (33, 34). This can to some degree be 
overcome by applying an additional washing 
step with PBS after exosomes are already 
isolated (32). Some protocols use a 0.22 µm 
Figure 2: Exosome composition. Exosomes consist 
of a lipid-bilayer that encapsulates a core of proteins 
and genetic material (miRNA, mRNA, mtDNA). On 
the membranes they display different types of 
proteins such as tetraspanins, cytoplasmic proteins, 
heat-shock protein and surface receptors. 
Tetraspanins are most commonly used as exosomal 
markers, for example CD63 and CD81 (12). 
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filtration step before the ultracentrifugation 
to further remove apoptotic bodies and larger 
microvesicles (14). However, that technique 
is also used for the preparation of liposomes 
by extrusion. In fact bigger lipid particles 
pushed through a filtration membrane can 
break into smaller particles, hence resulting 
in the opposite result that was initially 
intended (35). Therefore the use of this type 
of filtration in exosomes isolation is 
undesirable. Additionally, protein aggregates 
and larger microvesicles can be separated 
from exosomes by ultracentrifugation using a 
linear sucrose gradient where the difference 
in flotation velocity is used to divide these 
particles according to buoyant density. Most 
studies report that exosomes have a flotation 
density of 1.08-1.22 g/ml (28, 33).  
 
Various qualitative and quantitative methods 
can be used in a complementary fashion in 
order to characterize the exosome-containing 
pellet and assess its purity. Total particle 
concentration can be measured by 
nanoparticle tracking analysis (NTA), which 
is based on the Brownian motion of particles 
in solution. All particles in a fluid have a 
movement that is determined by their size 
and the temperature. In NTA, a laser beam 
illuminates the particles which generate a 
scatter signal that is sensed by a detector. 
These scattering particles are then 
individually tracked in a time-lapse video by 
the NTA software which calculates vesicle 
size and total concentration depending on 
their diffusion properties (36).  Another way 
of estimating the exosome concentration is 
based on the total protein content of 
exosomes. The protein content can be 
quantified using the bicinchoninic acid 
(BCA) colorimetric assay (37, 38). The assay 
spectrophotometrically measures the light 
absorption of a complex that is formed 
between the assay reagent and the proteins in 
the sample. The protein concentration is then 
calculated by plotting the signal from the 
sample against the standard curve obtained 
using bovine serum albumin (BSA) protein 
standards (38). The protein extracts can be 
further used to quantify the presence of 
exosomal markers (most often CD63 or 
CD81) or contaminants (endoplasmic 
reticulum or Golgi apparatus markers) (14, 
39, 40). Such quantification is most 
commonly performed by Western blot which 
is an analytical technique that can detect 
specific proteins in a sample. Briefly, 
proteins are first separated by size with gel 
electrophoresis and then transferred onto a 
membrane where they are stained with the 
specific antibodies targeting proteins of 
interest. (41). The full exosomal proteome 
can be characterized with high-throughput 
proteomic techniques, as for example with 
mass spectrometry (MS). MS is an analytical 
technique used for identification and 
quantification (under specific experimental 
configurations) of proteins in a sample. 
Firstly, proteins are proteolytically cleaved 
with a digestive enzyme (most often trypsin) 
into smaller peptides. These are then ionized 
and some selected ions are further 
fragmented, which result in mass over charge 
spectra. Data analysis allows comparing the 
obtained mass over charge ratios of the 
fragments against those of known sequences 
in a database. Taking into account also the 
intensities of the spectral features and the 
theoretical sequence and spectra of protein 
fragments, the peptides with best matching 
spectra are identified and assigned to the 
most probable protein they constitute (42).    
Gliomas and angiogenesis 
Glioma is a type of cancer that arises from 
glial cells that have gone through neoplastic 
transformation to turn into malignant tumor 
cells. There exist several types of glial cells 
(e.g. astrocytes, oligodendrocytes) and 
glioma can therefore form different types of 
tumors according to the originating glial cell 
type (43). For example, astrocytoma is a type 
of glioma that arises from astrocytes, the 
most abundant type of glial cells in the brain 
(43, 44). The World Health Organization 
(WHO) classifies malignant gliomas into the 
three stages II-IV according to their 
development stage which in turn correlates 
strongly with patient survival rate. Stages II 
and III are considered as low-grade gliomas, 
while the IV stage is highly malignant 
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glioma that is characterized by the poorest 
survival rate of patients (45). To elucidate 
the role of exosomes in brain cells, the two 
human-derived glioma cell lines, U87-MG 
and H4 were used. U87-MG cell line is a 
long established and well-studied grade IV 
glioma, also referred to as glioblastoma 
multiforme, the most malignant form of 
astrocytoma (46). H4 cell line was instead 
derived from a patient with neuroglioma, 
(low-grade astrocytoma) (47).  
 
Progression from low-grade malignancy to 
high-grade malignancy is in large driven by 
the increase in proliferative capacity of 
tumor cells and angiogenic events (i.e. 
formation of new blood vessels from the pre-
existing vasculature) in the hypoxic regions 
of the tumor (43, 48). Hypoxic regions are 
parts in the body that are low in oxygen and 
nutrients supply from the blood vessels 
which is a necessary requirement for a cell to 
properly function. The cells in the body are 
normally positioned in a close proximity at 
most 100 µm away from the blood  vessels 
where the diffusion of oxygen and nutrients 
from the vessels is still possible (48). Since 
the tumor cells rapidly proliferate, they can 
outgrow their blood supply which can in turn 
cause vascular endothelial injury resulting in 
a significantly lower oxygen levels or so 
called hypoxic regions (43, 45). Due to 
cellular need for delivery of nutrients from 
the blood, cells in those regions start dying 
which result in the tumor necrotic centers. 
Cells surrounding the glioma necrotic 
centers, are called pseudopalisading cells. 
They can start to secrete hypoxia-related 
angiogenic factors, such as vascular 
endothelial growth factor (VEGF), that 
stimulate microvascular proliferation and 
create new source of blood supply (43, 45, 
48). Consequently, the tumor may become 
even more progressive and possibly enriched 
in apoptosis-resistant clones that are able to 
survive hypoxic microenvironments (43). 
Necrosis and highly increased angiogenesis 
are the main histopathologic features of 
glioblastoma that distinguish it from the low-
grade astrocytomas (48).  
The intracellular events that induce tumor 
angiogenesis are highly connected to 
hypoxic microenvironment and are driven by 
hypoxia inducible factor 1 α (HIF-1α) and its 
downstream targets (49). HIF-1α is a 
constitutively expressed protein that is 
differentially altered under normoxia 
compared to hypoxia. In normoxia HIF-1α is 
hydroxylated at prolyl residues by 
hydroxylase enzymes. That allows the von-
Hippel-Lindau protein (pVHL) to 
ubiquitinate HIF-1α , leading to proteasomal 
degradation (50). In hypoxia however, these 
hydroxylases are inactivated because they 
require oxygen for catalysis of the 
hydroxylation reaction (48). Therefore, HIF-
1α protein remains stable in hypoxic 
condition and can translocate to the nucleus 
where it dimerizes with the HIF-1β subunit. 
The dimer can then bind to hypoxia-
responsive elements (HREs) which can 
activate the promoters of genes that are 
involved in various processes, such as 
angiogenesis, cell proliferation, survival, 
extracellular matrix metabolism and others 
(48). Among major angiogenesis driving 
factors that have been found upregulated in 
hypoxic cells are VEGF, VEGF receptors 
(VEGFR), angiopoietin and matrix 
metalloproteinases (MMPs) (51). VEGF is a 
growth factor that is abundantly expressed 
by hypoxic cells (in glioblastoma especially 
by pseudopalisades) and is released into the 
extracellular matrix (45, 52). The formation 
of gradients for VEGF and other 
proangiogenic factors in the 
microenvironment promotes the proliferation 
of endothelial cells as well as the formation 
of new vasculature (52). 
Hypoxic and oxidative stress 
According to previous studies, hypoxia is 
considered a major regulator of tumor 
development and aggressiveness but the 
underlying mechanisms of how the cells 
adapt or communicate with their surrounding 
microenvironment are still remaining 
questions (39, 49, 51). Cell-secreted 
nanovesicles, exosomes, may play an 
important role in that communication (28, 
39). Recent reports have shown that the 
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exosomes from hypoxic cells were excreted 
in higher amounts and were enriched in 
hypoxia-regulated mRNAs and proteins 
reflecting hypoxic status of donor cells (18, 
39, 53). Furthermore, hypoxic exosomes 
have been shown to mediate an angiogenic 
response by endothelial cells in vitro (28, 
39).  
 
In vitro the hypoxia response can be 
activated either physically or chemically. A 
hypoxia chamber can be used to create a 
controlled and isolated environment where 
the oxygen level can be reduced to reach 
near anoxia (0% O2). Chemically induced 
hypoxic response is instead reached using 
compounds that interrupt the HIF-1α 
pathway (54). For example, 2, 2’-dipyridyl 
(DIP) is an iron chelator that interrupts prolyl 
and asparaginyl hydroxylase enzymes (55, 
56). Normally, hydroxylases require oxygen 
but also iron as a cofactor for their activity. 
When the iron pool in the cell is depleted as 
it is with iron chelators, the hydroxylases are 
inactive (57). Consequently, HIF-1α is 
stabilized and can translocate into the 
nucleus where it induces a hypoxia response 
(55-57).  
Exosomes may also have an important role 
in cell communication in other types of 
stresses, such as oxidative stress (19). 
Reactive oxygen species (ROS), including 
hydrogen peroxide (H202), are normal 
byproducts of cellular aerobic metabolism 
which can be neutralized by the cells innate 
cellular defense mechanisms (e.g. 
antioxidants, enzymatic scavengers) (19, 58). 
However, if the ROS levels increase to a 
point where the cell cannot eliminate them 
properly, ROS can cause serious damage to 
DNA, proteins and lipids which in turn can 
lead to a wide variety of diseases (58). 
Depending on the ROS concentration, the 
cellular response can range from 
proliferation, growth arrest and senescence 
to cell death. All these responses are 
activated by intracellular stress signaling 
pathways. However, it has also been reported 
that cells exposed to a low concentration of 
ROS can induce a tolerance to a higher dose 
of oxidative stress (59). Furthermore, a 
recent study showed that exosomes from 
donor cells exposed to oxidative stress carry 
protective signals to recipient cells and this 
way induce a tolerance resulting in reduced 
cell death (19).  
Hypothesis 
The main goal of this study was to establish 
a routine procedure for exosomes analysis 
including collection, isolation, quantitative 
and qualitative characterization. Since 
exosomes are known to be secreted under 
stress conditions and carrying signals 
important for a variety of cellular process 
(e.g. angiogenesis, stress resilience, tumor 
invasion, etc.) we set up a model of stress in 
glioma cell lines in order to study the 
differential release of exosomes. We 
hypothesized that U87-MG and H4 cells 
exposed to stress conditions would produce 
more exosomes than those in control 
environment. Moreover, we expect 
exosomes to carry stress-related information 
and we aimed to characterize their content in 
detail. The U87-MG cell line was used as a 
starting point to reproduce recent results (39) 
together with the H4 cell line. This initial set 
of experiments serves as a basis for further 
studies.  
 
Materials and Methods 
Cell culture 
Human glioma cell lines (U87-MG and H4) 
were purchased from American Type Culture 
Collection (ATCC) and  cultured in 
Dulbecco’s modified Eagle medium 
(DMEM), supplemented with 10% dFBS 
(FBS with removed exosomes), 2 mM L-
glutamin, 1 g/l glucose, 100 µg/ml 
streptomycin and 100 U/ml penicillin. All 
cells were cultured in a humidified incubator, 
set at 5% CO2 and 37ºC.   
MTT assay 
Cells were plated in 96-well plates at a 
density of 4000 cells/cm2 in a total volume 
of 100 µl of DMEM medium without phenol 
red, supplemented as described above. On 
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the day 1 after seeding, 25-100 µM 
concentration range of DIP and 10-400 µM 
concentration range of H202 were added into 
the wells. Since the DIP is dissolved in 
ethanol, that was added to the cells in the 
same concentrations as with DIP treatment 
and was used as control. The control for 
H202- treated cells was standard medium. 
Cells were then incubated for 48 hours and 
cell viability was measured with the 3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazoli-
um Bromide (MTT). MTT is reduced into 
insoluble formazan by cellular NADPH-
dependent oxidoreductase enzymes. Those 
are active only in viable cells, thus the cell 
viability is measured according to the 
amount of produced formazan. Tetrazolium 
dye MTT in 5mg/ml concentration was 
added in 1:10 ratio to the wells and 
incubated in the cell culturing incubator for 3 
h in dark. Formazan crystals were dissolved 
by adding 100 µl of acidified isopropanol 
that was prepared from 0.1 N HCl mixed in 
isopropanol. The plate was covered with 
aluminum foil and incubated at room 
temperature for 20 min. The optical density 
of formazan concentration was measured in a 
platereader at 570 nm. The signal at 690 nm 
was used to determine the background noise 
level and was subtracted. The absorbance 
values of formazan were used to plot dose-
response curves for the two stress factors.  
Cell counts with bright-field analysis  
The experiment was designed in the same 
way as for the MTT assay, though black 
optical bottom plates were used. 48 hours 
after treatment cells were counted with the 
bright-field stain free analysis using the 
SpectraMax MiniMax 300 Imaging 
Cytometer.  
Exosome isolation 
U87-MG and H4 cells were cultured in 
DMEM supplemented with 10% dFBS to a 
high density. dFBS was obtained by 
ultracentrifugation using a Beckman 
centrifuge and rotor (70.1 Ti)  at 120 000 g 
for 16h. Supernatant of FBS was filtered 
through 0.2 µm membrane filter prior to use 
in cells culture. The cells were cultured for 
48 h in different conditions: control medium, 
85 µM DIP (U87-MG), 60 µM DIP (H4) or 
50 µM DIP (H4) and 70 µM H202 (U87-MG) 
or 25 µM H202 (H4). Exosomes were 
isolated by differential ultracentrifugation. 
At the end of the 48 h harvest time the 
conditioned media was collected for 
exosome isolation and the cells were 
trypsinized and counted with the use of a 
hemocytometer. Conditioned media were 
then centrifuged at 500 x g for 10 min to 
pellet the cells and cell debris. Supernatants 
were further centrifuged at 16500 x g at 4ºC 
for 20 min. Exosomes were in the end 
pelleted by ultracentrifugation at 120000 x g, 
4ºC for 70 min. Exosomes were resuspended 
in 100 µl of PBS and frozen in -80ºC for 
further analyses. 
Nanoparticle tracking analysis (NanoSight 
™) 
Isolated exosomes were diluted in PBS 100x 
and frozen in -80ºC till NTA analysis using 
NanoSight LM10 system, configured with a 
405 nm laser and a high sensitivity digital 
camera system. Samples were injected in the 
prism chamber with a syringe and videos 
were collected and analyzed using the NTA-
software. The same acquisition and analysis 
settings were used for different analysis. 
Each sample was measured three times. 
Protein extraction and assay of protein 
concentration 
Exosomes dissolved in PBS were broken 
down with the 3% SDS in RIPA buffer with 
protease inhibitors. RIPA buffer was 
prepared from 50 mM Tris-HCl, 137 mM 
NaCl, 1% Triton X-100, 0.1% SDS, one 
tablet of protease inhibitors (Roche) and 
miliQ water and the end pH was adjusted to 
7,6-8.  After adding 3% SDS in RIPA to 
exosomes, the Eppendorfs were vortexed and 
incubated on ice for 5 min. The protein 
content was then measured with Pierce® 
BCA protein Assay Kit by Thermo 
Scientific. The exosome lysates, plate blank 
(PBS), sample blank (3% SDS in RIPA 
buffer with PBS) and the BSA standards 
were pipetted into the wells of a 96-well 
half-bottom plate in amount of 12.5 µl. To 
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the wells was then added 100 µl of working 
reagent and the plate was slightly shaken and 
incubated for 30 min in 37 ºC. The plate was 
cooled to room temperature and the 
absorbance was measured at 562 nm in a 
plate reader (SpectraMax). The absorbance 
of the plate blank was subtracted from all the 
wells and the sample blank was substracted 
from the samples. The total protein 
concentration of exosomes was determined 
from the standard curve, plotted from 50-
2000 µg/ml BSA standard concentration 
range.  
Tandem mass spectrometry (MS/MS) 
using tandem mass tags (TMT) 
Mass spectrometry based proteomics was 
performed by the Proteomic Core Facility at 
Sahlgrenska academy, Gothenburg 
University.  
 
Sample preparation for proteomic analysis 
100 µg of total protein of each sample and 
100 µg of a pool containing equal amounts 
of all samples were diluted with lysis buffer 
to a volume of 70 µl. The samples were 
reduced by the addition of  2M DL-
Dithiothreitol (DTT) to 100 mM and then 
trypsin digested using the filter-aided sample 
preparation (FASP) method modified from 
previously published protocol (60). After 
centrifugation the filtrates were subjected to 
isobaric mass tagging reagent TMT® 
according to the manufacturer’s instructions 
(Thermo Scientific). Each sample was 
labelled with a unique tag from a TMT 6plex 
isobaric mass tag labeling kit, 
(http://www.piercenet.com/product/amine-
reactive-6-plex-tandem-mass-tag-reagents). 
After TMT labeling, the samples in this set 
were pooled and concentrated. The peptides 
were further purified and fractionated into 12 
fractions which were subsequently desalted.  
 
LC-MS/MS Analysis 
The dried fractionated and desalted 6-plexed 
TMT-labeled sample was reconstituted with 
15 µl of 0.1 % formic acid (Sigma Aldrich)) 
in 3% acetonitrile and analyzed on an 
Orbitrap Fusion Tribrid mass spectrometer 
interfaced to an Easy-nLC II (Thermo Fisher 
Scientific). A second MS/MS analysis was 
performed excluding peptides already 
detected. 
 
Database Search for protein TMT 
Quantification  
All MS raw data files for the TMT set were 
merged for relative quantification and 
identification using Proteome Discoverer 
version 1.4 (Thermo Fisher Scientific). A 
database search was performed with the 
Mascot search engine (Matrix Science) using 
the human Swissprot Database version July 
2014 (Swiss Institute of Bioinformatics, 
Switzerland). Only peptides unique for a 
given protein were considered for relative 
quantitation, excluding those common to 
other isoforms or proteins of the same 
family. The quantification was normalized 
using the protein median. The results were 
then exported to Excel for manual data 
interpretation, calculating fold changes and 
statistical analysis using Welch´s t-test in R. 
 
Results 
 
Modeling of stress conditions in glioma 
cell lines 
Determination of suitable stress conditions 
for glioma cell lines U87-MG and H4 with 
two stress factors, DIP and H202, was 
assessed with the MTT colorimetric assay 
and with the cell count using bright-field 
analysis by SpectraMax MiniMax 300 
Imaging Cytometer.  The dose-response 
curves to 25-1000 µM concentration range of 
DIP and 10-400 µM concentration range of 
H202 are shown in Figure 3. Data points 
represent mean values of multiple individual 
experiments (as described below) that were 
performed at different time points using 
different concentration ranges of stress 
factors. Therefore, the calculated average 
value of each concentration was not always 
calculated from the same number of 
experiments. In the dose-response curve of 
U87-MG cell line, the data points represent 
four individual experiments with the 
exception of three and two concentrations 
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Figure 3: Dose-response curves from the MTT assay. 
Absorbance of formazan, measured on the 2nd day 
after the addition of stress factors in different 
concentrations, is representing amount of viable U87-
MG and H4 cells. Absorbances of formazan from 
cells treated with different concentrations of stressors 
were compared to the control and the growth (y- axis) 
was calculated resulting in the dose-response curves 
of (A) DIP- treated (x-axis) and (B) H202-treated (x-
axis) cells. Fitted curves were plotted in GraphPad 
Prism 6.04 using log (inhibitor) vs. response nonlinear 
fit with variable slope. In all cases the bars denote ± 
standard deviation (SD) values. Dotted lines represent 
inhibitory concentrations IC25 and IC50 respectively 
which is presented in Table 1. 
 
(for DIP and H202 respectively) where mean 
values of two individual experiments were 
used. In the case of H4 cell line, the data 
points represent mean values of three 
individual experiments with the exception of 
two concentrations in H202-treated cells 
where was used mean value of 1 individual 
experiment. 
U87-MG cell line is more resistant to both 
types of stresses than H4 as shown by the 
shift to the right. Also, hydrogen peroxide 
induces its full inhibition of cell growth at  
 
 
 
 
 
 
 
Figure 4: Dose-response curves from the cell counts 
using bright-field analysis. Cells were counted using 
bright-field microscopy on the 2nd day after the 
addition of stress factors in different concentrations. 
Cell counts of treated cells were divided with control 
counts, resulting in % of growth inhibition (y- axis), 
in (A) DIP- treated (x-axis) and (B) H202-treated (x-
axis) cells. . Data points represent mean values of 
triplicates in the experiment and error bars denote ± 
(SD) values. Dotted lines represent inhibitory 
concentrations IC25 and IC50 respectively. 
 
lower concentration than DIP, which in fact 
does not inhibit cell growth completely (at 
least not in this concentration range). On the 
other hand, growth inhibition is more rapid 
MTT  
assay 
DIP (µM) H202 (µM) 
IC25 IC50 IC25 IC50 
U87-MG 81 99 44 89 
H4 57 66 31 63 
Table 1: Inhibitory concentration (IC) values from the 
MTT assay. IC25 and IC50 values were calculated 
from the dose-response curves of U87-MG and H4 
cell lines (Figure 3) in GraphPad Prism 6.04 and they 
represent the concentrations (µM) of stress factors that 
inhibit cell growth by 25% and 50% respectively.  
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in DIP-treated cells compared to more 
gradual inhibition by H202. Inhibitory 
concentrations (IC) were calculated from the 
plotted dose-response growth curves and 
they represent the effectiveness of a 
substance in inhibiting cell growth.  IC25 
and IC50 values, concentrations of a 
substance that inhibits cell growth for 25% 
and 50% respectively, were interpolated at  
Y=75 and Y=50 (Table 1). In line with the 
lower resistance of H4, the lower IC values 
of DIP and H202 are needed to inhibit its cell 
growth for 25% and 50%. 
Cell count by bright-field analysis with 
SpectraMax MiniMax 300 Imaging 
Cytometer resulted in rather divergent dose-
response curves to that of MTT assay (Figure 
4) due to high errors. One has to take into 
consideration that in higher concentrations of 
DIP and H202, cells underwent cell death that 
was visible under bright-field microscope 
imaging, thus apoptotic bodies in a stain-free 
image lead to increasingly higher errors in 
the software automatized cell count with 
increasing concentrations of stress factors 
Dose-response curves for DIP-treatment 
have similar shapes and the trend between 
the two cell lines to that of MTT assay. 
Whereas the dose-response curves for H202-
treatment are not showing the same trend as 
in MTT assay due to the fact that the dead 
cells in the U87-MG cell line were still 
mostly attached and counted as alive. The IC 
values from that experiment were not 
calculated since the dose-response curves are 
not reliable enough due to high errors. 
 
Cells morphology observations 
Upon collection of the supernatants, cell 
images were routinely acquired. We noticed 
that U87-MG cells changed morphology 
when DIP-treated but not when H202-treated. 
Normally, U87-MG cells are elongated but 
in mimicked hypoxia stress they shrank in 
size and looked rounded (Figure 5) which to 
our knowledge has not been known before. 
We have not observed that morphology 
change in H4 cell line.  
 
Quantitative analysis of exosomes isolated 
from glioma cell lines under hypoxic and 
oxidative stress conditions. 
Exosomes, isolated from U87-MG and H4 
cell lines under two stress conditions 
(hypoxia and oxidative stress), were broken 
down and the total µg of proteins in the 
samples were measured with the BCA assay. 
The total mass of proteins in the samples was 
then divided by the number of cells present 
in the flasks on the day of collection in each 
condition. That calculation resulted in the 
measurement of µg of released proteins per 
million cells which was used to compare 
different samples among each other in terms 
of estimated exosome quantification. Three 
separate experiments have been done with 
both cell lines with the collection of 
exosomes from 10% dFBS medium under 
two stress conditions. In order to assess the 
influence of hypoxic and oxidative stress, 
preliminary IC25 concentrations of stress 
factors DIP and H202 were used. The values 
Figure 5: Morphology changes in DIP-treated U87-
MG cells. Pictures were taken under 100 x
magnifications with Leica objective on the day of
exosomal collection in (A) control and (B) DIP-
treated cells (48h exposure). DIP-treated cells
changed the morphology from extended to rounded
cells due to hypoxic stress.  
A 
B 
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Figure 6: Quantification of exosomes with BCA
protein measurements in three indiviual
experiments. Graph shows µg of proteins
secreted  from 106 cells in control environment,
hypoxia (DIP) and oxidative stress (H202) in
(A) U87-MG and (B) H4 cell lines. The
experiments correspond to the ones in the Table
2. Experiment 1 from U87-MG cells was
obtained from highly confluent cells and the rest
were obtained from cells in medium confluency. 
used in this set of experiments differ from 
the IC25 values reported in Table 1 as they 
were calculated from the initial MTT assays. 
Measurements of µg of released proteins per 
million cells are presented as separate 
experiments in Figure 6 where they 
correspond to the ones in Table 2. 
 
There is no visible trend that the cells under 
stress conditions produced more exosomes 
than in control environment. In U87-MG cell 
line, two experiments showed slight decrease 
in the amount of exosomes released under 
hypoxia and slight increase of released 
exosomes in oxidative stress. On the other 
hand, the last experiment (sample 3) resulted 
in just the opposite trend. The amount of 
released proteins per million cells in the 
latter sample is also distinct from the other 
two experiments. Amounts of isolated 
exosomes in H4 cell line did not change 
drastically between the treatments with the 
exception of one peak in DIP-treated cells 
where was detected 2.7 fold increase in 
exosomes released per million cells. We also 
noticed that the confluency of cells may have 
an impact on the amount of released vesicles. 
Figure 6A and Table 2 show that when the 
U87-MG cells were fully confluent they  
Table 2: Quantitative analyses of exosomes from U87-MG and H4 cells. Both cell lines were treated for 48 
h with stress factors prior exosome collection. U87-MG cells were treated with 85 µM concentration of 
DIP and 70 µM concentration of H202 while the H4 cells were treated with 60 (in 1st experiment) or 50 ( in 
2nd and 3rd experiment) µM concentration of DIP and 25 µM concentration of H202. On the day of collection 
number of cells was counted and the isolated exosomes were quantified with BCA.  
13 
 
produced considerably less exosomes as 
when in lower confluency with the exception 
of sample 3. For instance, U87-MG cells in 
low confluency (sample 4) in the control 
condition released vesicles accounting for 
7.2 µg of proteins/106 cells which is around 
3.7 fold increase than the cells in high 
confluency (Table 2).  Also, in that sample 
we noticed that the cells in hypoxia stress 
produced 2.2 times more exosomes than in 
control (Table 2). We observed the same 
response from exosomes collected under 
serum free conditions (DMEM medium with 
B27 supplement and epidermal growth factor 
(EGF)). U87-MG cells produced 4.1 µg of 
proteins/106 cells (sample 5) in control, 
which accounts for a 2-fold increase 
compared to high confluent cells, and 2.9 
times more in DIP-treated cells (Table 2).   
NTA measurements of particle 
concentrations and size distributions of 
exosomal samples 
Total particle concentration and size of six 
samples from H4 cell line (samples 2 and 3 
in Table 2) were determined with the NTA. 
All the samples were frozen after exosome 
isolation at -80ºC until the NTA 
measurements. Numbers of particles per ml 
were converted to percentages of released 
vesicles in DIP and H202-treated cells 
compared to control as an estimate of 
quantitative changes in production of 
exosomes. Percentages of released vesicles 
obtained from NTA measurements were 
differing on average by 18 % from the BCA 
measurements of total protein content 
(Figure 7), possibly indicating some protein 
contaminations in the exosomes samples. As 
a measurement related to sample purity the 
ratio of particle (in 1010/ml) to protein 
(µg/ml) (Table 3) was calculated as proposed 
by a study from Webber et al. Ratio of 
≥3×1010 particles per µg of protein is 
proposed to be a measurement of high purity 
samples and a ratio of 1×1010 is proposed to 
contain around 50% of contaminant proteins 
(61). If our sample ratios are examined using 
that definition, then the samples are of 
medium or lower purity.   
 
 
Figure 7: Comparison of percentages of cell-released 
particles from two stresses (hypoxia and oxidative 
stress) to control environment from the data obtained 
by two methods as a measurement of exosomal 
content. Amount of exosomes was measured as total 
protein content with BCA assay (light columns) and 
as a total amount of particles/ml with NTA (darker 
columns). The estimation of exosome amount is 
differing from one method to another in average of 
18%.  
 
Table 3: Exosome purity measurements from H4 cells 
using the ratio of particle to protein. The ratio is 
calculated from the particle count by Nanosight (1010 
particles/ml) that is divided by the protein content 
(µg/ml) measured with BCA. It tells how pure the 
vesicles are with the determination of protein 
contaminants. The more contaminant proteins are 
there in the sample the lower ratio. According to 
Webber et al. the ratio of 3x1010 particles per µg of 
protein is considered as high purity sample and a ratio 
of 1×1010 is proposed to contain around 50% of 
contaminant proteins. Experiments correspond to the 
ones in Figure 6 and Table 2. 
H4	
Experiment Control  DIP  H202 
2	 1,57  1,50  1,93 
3	 1,70  2,09  2,07 
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Size distributions of samples were varying 
from 30-220 nm and the particle sizes were 
in most cases characterized by two or more 
peaks (graphs are not presented). The first 
peak was visible at 30-40 nm, the second at 
ca. 100 nm while the third one at ca. 200 nm. 
Shoulders in the distribution were also 
observed at higher sizes. Besides the 
probable presence of bigger vesicles than 
exosomes (above 200 nm) also the formation 
of particles aggregates and/or protein-
particles might occur during freezing and 
thawing of samples.    
High-throughput proteomic studies of 
exosomal proteome  
Exosome proteomes, isolated from control 
and DIP-treated cells in B27+EGF medium 
(sample 5 in Table 2), were analyzed with 
the tandem mass spectrometry (MS/MS) 
using TMT. High-throughput proteomic 
study of control and DIP-treated sample 
triplicates resulted in the unambiguous 
detection of 441 proteins. In this set we 
found most of the known exosomal markers, 
such as CD63, CD9, CD82, HSP70, HSP90 
and syntenin. We did not detect cell 
contaminant proteins Golgi apparatus (GA) 
marker GM130, mitochondrial marker 
VDAC1 and endoplasmatic reticulum (ER) 
marker calreticulin or calnexin. Among the 
detected proteins, 67 proteins had a 
significance value for the fold change of p < 
0.001. The fold change of proteins in 
exosomes collected from DIP-treated cells 
compared to the control samples showed 33 
proteins with fold changes with greater than 
two times. Among those, 11 proteins showed 
a decrease in fold change lower than 0.5 and 
22 proteins higher than 2. These proteins 
were analyzed in the Database for 
Annotation, Visualization and Integrated 
Discovery (DAVID) respectively, resulting 
in different annotation clusters (62). Up-
regulated proteins showed the cluster of 
ribosome proteins such as ribosomal 
subunits and ribonucleoproteins (Appendix 
1). Instead, down-regulated proteins were 
clustered in cellular processes involved in 
the modulation of extracellular matrix. 
Among those were detected collagen, von 
Willebrand factor, cell adhesion proteins and 
extracellular matrix proteins (Appendix 2).  
 
Discussion 
Membrane vesicle trafficking is considered 
to be an important way of cell 
communication. Particularly exosomes are 
believed to play an important role as 
intercellular messengers since their cargo is 
believed to be packaged selectively in the 
vesicles (9, 14) and most cells in the human 
body appear to have a capability to release 
such vesicles. In this study, we set up a 
routine procedure of isolating and 
characterizing these vesicles. We also 
established a model for hypoxia and 
oxidative stress in two glioma cell lines in 
order to study whether the effect of such 
stressors has the impact on the release of 
exosomes in U87-MG and H4 cell lines. 
Here we present the preliminary data which 
does not show a notable trend in differential 
release of exosomes by cells in stress 
compared to control environment. However, 
we found initial evidence that the content of 
exosomes illustrate the metabolic state of 
donor cells.  
The models of hypoxia and oxidative stress 
were assessed with the MTT assay and cell 
counts with bright-field analysis, resulting in 
dose-response curves of glioma cell lines 
(Figure 3 and Figure 4). Cell counts with 
bright-field analysis are in general very 
precise way of estimating cell viability. In 
our experiment however the cell counts were 
aggravated due to increased cell death at 
higher concentrations of stress factors. 
Floating apoptotic bodies gave a high 
background and the optical cytometer could 
not count with the same precision as when 
there was no or very little cell death, 
therefore the dose-response curves could be 
compromised. Since the experiment was 
repeated several times with the MTT assay 
and only one time with the bright-field cell 
counts, the former assay is more informative. 
These show that the two stress factors have 
different effectiveness on the growth 
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inhibition in cell lines. Hydrogen peroxide is 
more potent stress factor that elicited full 
effect at its high concentration compared to 
DIP that elicited a partial effect on growth 
inhibition. On the other hand, DIP had more 
abrupt effect (a steeper slope) with 
increasing concentrations than H202 that 
induced a more gradual effect. DIP and H202 
stress factors affected H4 glioma cell line 
more strongly than the U87-MG cell line. 
Higher sensitivity of the H4 cell line could 
correlate to its lower malignant state 
compared to U87-MG. During the 
progression from low to high grade-
malignancy many genetic alterations occur 
that contribute to higher resistant state of 
glioblastoma multiforme. These include 
stronger activation of growth signaling 
pathways involving EGFR, PTEN and Akt 
or genes that are involved in the cell cycle 
control such as p53 and Retinoblastoma 
which also decrease apoptosis rate (43).   
For the induction of stress conditions in our 
experiments we decided to use IC25 values 
from MTT assay of stress factors in order to 
assess sufficient stress environment without 
inducing excessive cell death. During the 
apoptotic processes, cells start to condense 
and fragment, resulting in the release of 
apoptotic bodies, which carry all sorts of cell 
material. These vesicles can vary in size 
from 500-2000 nm (3) and their density can 
overlap with the exosomes which can cause 
problems during the isolation and analysis 
processes. This is a possible source of 
contamination in our experiments. Therefore 
the presence of such contaminants or any 
other possible unwanted impurities (e.g. 
microvesicles, protein aggregates) but also 
exosomal markers are usually routinely 
checked with Western blot. In our study, the 
proteomic analysis gives us first indication in 
this direction. Even though we did not find 
typical contaminants in the proteomics 
samples, the absence of these proteins in the 
mass spectrometry results does not allow to 
completely exclude possible impurities. The 
MS/MS technique detects only the proteins 
that are most abundant, therefore the 
contaminants might still be present in the 
sample but at lower concentrations (42). 
Nevertheless, among the detected proteins 
were for instance main exosomal markers, 
suggesting that exosomes represented a large 
part of our samples. However, further 
characterization steps are necessary, that will 
determine the purity of the exosome 
preparation. These for example include 
Western blot analysis for exosomal markers 
and contaminants, sucrose gradient 
centrifugation for confirmation of proper 
density and transmission electron 
microscopy (TEM) to morphologically 
confirm their identification as exosomes 
(32). In summary, we are confident from the 
NTA and MS/MS analyses that the particles 
we were analyzing were exosomes. But the 
extent of contamination remains somewhat 
unknown and more contamination might 
occur in samples where the cell death was 
increased. For example, in the sample 1 of 
H4 cell line (Figure 6, Table 2), there were 
only present 28% of cells in DIP- treated 
samples compared to control. This might not 
only reflect growth arrest but also cell death, 
resulting in such low cell numbers. 
Therefore, the exosomal fraction might also 
contain increased amount of apoptotic 
bodies, which in turn raised the count for µg 
of proteins release per million cells. 
Similarly, in DIP-treated U87-MG cells in 
experiment 4 (Table 2) we detected much 
more proteins released per million of cells 
compared to control (2.2 times more) while 
there was 63% decrease in cell growth. 
Hence, increase in released µg proteins/106 
cells might not be due to greater cell-cell 
communication in stress conditions but 
rather due to contaminations from apoptotic 
bodies that gave false positive results.  
Exosome concentration is very often 
measured as total protein content, present 
both in the core and in the lipid membrane, 
as a complementary measurement to the total 
particle concentration. In our experiments we 
analyzed exosomes mainly with the BCA to 
obtain measurements of total protein content 
as a determination of quantity changes in 
released vesicles in two stress conditions. 
We could observe some difference among 
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conditions, but not a notable trend. Further 
data collection and analysis are needed prior 
to drawing conclusions. The isolation of the 
exosomes constitutes a rather time 
consuming process, with materials yields 
being the main bottleneck in these studies. In 
future experiments we plan to scale up the 
amounts of cells and centrifugation volumes. 
From the data that we obtained we also 
noticed that cells which did not reach high 
confluency released more exosomes than 
very confluent cells. This might happen due 
to lower metabolism of confluent cells, 
which results in diminished cell signaling 
and metabolism. The result enables us to 
improve the cell densities used for harvest, 
hence the yield of pelleted material. By 
collecting the exosomes during the growing 
phase we also expect to improve 
reproducibility and facilitate data 
interpretation. 
Comparison of particle concentrations from 
the NTA measurements with the protein 
amounts obtained with the BCA 
measurements suggests that the exosome 
samples 2 and 3 of H4 cell line were not 
highly purified. To improve the isolation and 
purification of exosomes, an additional 
washing step could be added in the process. 
This could improve the purity of the samples 
but would decrease the yield of isolated 
exosomes. According to the finding by 
Webber J. et al. (2013), the additional 
washing step might improve this ratio as 
little as 2-fold and therefore other 
approaches are more desired such as sucrose 
gradient centrifugation (61). The size 
distribution of particles in the sample 
showed that there was more than one peak in 
the size, which could be either due both to 
contaminations that occurred during sample 
preparation and to particles aggregation that 
might occur during freezing and thawing. 
We have noticed that if the samples were 
analyzed fresh, within few days after 
isolation, the size distribution was more 
consistent and did not show additional peaks 
in contrast to the samples that were analyzed 
after freezing and thawing.  
It has been reported that exosomes from 
material of highly malignant glioblastoma 
patients and U87-MG glioma cell line are 
enriched in hypoxia-regulated proteins as for 
example matrix metalloproteinases, IL-8, 
PDGFs and caveolin 1(39). In our study we 
wanted to reproduce previously published 
results and examine whether U87-MG 
glioma cell line under DIP-induced hypoxia 
also produce exosomes enriched in 
angiogenic proteins. We however did not 
find any of these or other angiogenic proteins 
in hypoxic exosomes, possibly because the 
hypoxic stress on cells was not sufficient. 
DIP only mimics the HIF-1 response of 
hypoxia and other pathways involved in 
hypoxia may not be altered under DIP 
treatment. Moreover, to properly monitor 
cellular stress it would be interesting to look 
at the gene expression level of hypoxia-
regulated genes, e.g. with real-time 
polymerase chain reaction (qPCR) or RNA 
microarrays.  As a candidates could be for 
example chosen genes CA9 and EGFR, since 
the expression of both these genes is strongly 
connected with the HIF-1 activity (63, 64). 
However, DAVID functional annotation 
clustering of proteins with fold change of 
more than 2 in our experiment showed that 
these exosomes were enriched in ribosomal 
proteins and depleted in proteins involved in 
the modulation of extracellular matrix 
(ECM) compared to control exosomes. 
Explanation for this could be that the 
exosomes represent the intracellular 
cytoplasmic content of cells. Cells under 
stress become more metabolically active, 
resulting in increased ribosomal biogenesis 
(65) and therefore the higher enrichment of 
ribosomal proteins in exosomes might reflect 
increased cellular translation. However, 
depletion of ECM proteins might indicate a 
differential need for those proteins due to 
morphological changes that cells experience 
under hypoxic stress (Figure 5). DIP-treated 
cells became more rounded and therefore 
might not need as many cell adherent 
proteins as the normally shaped cells. 
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Conclusion 
We set up the methods for exosomal 
isolation and two characterization techniques 
NTA and BCA. In all preparations that we 
analyzed we could confirm the presence of 
exosomes, however, verification of the purity 
of the exosomal samples remains an 
important issue. Further analysis will include 
Western Blots analysis of common 
contaminants, gradient centrifugations and 
TEM microscopy. Our data nevertheless 
show initial evidence that the exosome 
content reflects the inner metabolic status of 
cells. The study did not yet answer the 
question whether glioma cells exposed to 
hypoxic and oxidative stress produce more 
exosomes than the cells in standard culture 
conditions and more experiments are needed 
before making final conclusions.  
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Supplementary information 
Appendix 1: 22 proteins with the fold change of more than 2 were analyzed in DAVID database resulting in 11 
clusters. Count is representing number of proteins involved in the different processes in the cell or cellular part. 
P-value and Benjamini are the statistical measurements of significance where the lower number means higher 
significance. 
Proteins with fold change more than 2    
22 DAVID IDs     
Annotation Cluster 1  Enrichment Score: 7.22  Count  P_Value  Benjamini 
SP_PIR_KEYWORDS  ribonucleoprotein  12 1.5E-15  9.5E-14 
GOTERM_BP_ALL  translational elongation  8 5.6E-11  1.6E-8 
SP_PIR_KEYWORDS  ribosome  7 1.3E-10  2.6E-9 
GOTERM_CC_ALL  cytosolic ribosome  7 5.3E-10  2.0E-8 
SP_PIR_KEYWORDS  protein biosynthesis  8 7.9E-10  1.2E-8 
SP_PIR_KEYWORDS  ribosomal protein  8 7.9E-10  1.2E-8 
KEGG_PATHWAY  Ribosome  8 1.0E-9  7.3E-9 
GOTERM_MF_ALL  structural constituent of ribosome  8 1.9E-9  7.2E-8 
GOTERM_CC_ALL  ribosome  8 5.0E-9  9.2E-8 
GOTERM_BP_ALL  translation  9 8.3E-9  1.2E-6 
GOTERM_CC_ALL  cytosolic large ribosomal subunit  5 1.3E-7  1.6E-6 
GOTERM_CC_ALL  ribosomal subunit  6 4.4E-7  4.6E-6 
GOTERM_CC_ALL  cytosolic part  6 1.0E-6  7.6E-6 
GOTERM_CC_ALL  large ribosomal subunit  5 1.3E-6  8.9E-6 
GOTERM_MF_ALL  structural molecule activity  8 1.5E-5  2.9E-4 
GOTERM_CC_ALL  cytosol  9 1.2E-4  7.3E-4 
GOTERM_BP_ALL  cellular protein metabolic process  10 2.8E-3  5.6E-2 
GOTERM_CC_ALL  cytoplasmic part  13 6.4E-3  2.5E-2 
GOTERM_BP_ALL  protein metabolic process  10 9.7E-3  1.5E-1 
Annotation Cluster 2  Enrichment Score: 6.45  Count  P_Value  Benjamini 
GOTERM_CC_ALL  ribonucleoprotein complex  15 3.7E-17  2.8E-15 
GOTERM_CC_ALL  macromolecular complex  18 6.7E-10  1.7E-8 
GOTERM_CC_ALL  non-membrane-bounded organelle  16 1.0E-8  1.5E-7 
GOTERM_CC_ALL  intracellular non-membrane-bounded organelle  16 1.0E-8  1.5E-7 
GOTERM_CC_ALL  intracellular organelle  19 1.4E-3  7.3E-3 
GOTERM_CC_ALL  organelle  19 1.4E-3  6.9E-3 
GOTERM_CC_ALL  cytoplasmic part  13 6.4E-3  2.5E-2 
GOTERM_CC_ALL  cytoplasm  16 8.2E-3  2.9E-2 
Annotation Cluster 3  Enrichment Score: 4.2  Count  P_Value  Benjamini 
GOTERM_CC_ALL  macromolecular complex  18 6.7E-10  1.7E-8 
SP_PIR_KEYWORDS  acetylation  16 2.6E-9  3.2E-8 
GOTERM_BP_ALL  translation  9 8.3E-9  1.2E-6 
GOTERM_BP_ALL  gene expression  17 3.3E-8  3.2E-6 
GOTERM_CC_ALL  intracellular organelle part  17 9.3E-7  8.6E-6 
GOTERM_CC_ALL  organelle part  17 1.0E-6  8.3E-6 
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GOTERM_BP_ALL  cellular macromolecule biosynthetic process  14 1.4E-5  1.0E-3 
GOTERM_BP_ALL  macromolecule biosynthetic process  14 1.5E-5  8.8E-4 
GOTERM_BP_ALL  cellular macromolecule metabolic process  17 1.0E-4  4.3E-3 
GOTERM_CC_ALL  cytosol  9 1.2E-4  7.3E-4 
GOTERM_BP_ALL  cellular biosynthetic process  14 1.4E-4  4.9E-3 
GOTERM_BP_ALL  biosynthetic process  14 1.9E-4  6.0E-3 
GOTERM_BP_ALL  macromolecule metabolic process  17 3.7E-4  9.5E-3 
GOTERM_CC_ALL  intracellular organelle  19 1.4E-3  7.3E-3 
GOTERM_CC_ALL  organelle  19 1.4E-3  6.9E-3 
GOTERM_BP_ALL  cellular metabolic process  17 2.7E-3  5.7E-2 
GOTERM_BP_ALL  cellular protein metabolic process  10 2.8E-3  5.6E-2 
GOTERM_CC_ALL  intracellular part  20 3.4E-3  1.5E-2 
GOTERM_BP_ALL  primary metabolic process  17 4.6E-3  8.4E-2 
GOTERM_CC_ALL  intracellular  20 6.1E-3  2.5E-2 
GOTERM_BP_ALL  protein metabolic process  10 9.7E-3  1.5E-1 
GOTERM_BP_ALL  metabolic process  17 1.6E-2  1.9E-1 
GOTERM_BP_ALL  cellular process  19 8.6E-2  5.9E-1 
Annotation Cluster 4  Enrichment Score: 2.81  Count  P_Value  Benjamini 
GOTERM_BP_ALL  RNA processing  7 8.0E-5  3.8E-3 
GOTERM_BP_ALL  RNA metabolic process  8 2.0E-4  5.7E-3 
GOTERM_BP_ALL  RNA splicing, via transesterification reactions  4 1.2E-3  2.9E-2 
GOTERM_BP_ALL  RNA splicing, via transesterification reactions with 
bulged adenosine as nucleophile  
4 1.2E-3  2.9E-2 
GOTERM_BP_ALL  nuclear mRNA splicing, via spliceosome  4 1.2E-3  2.9E-2 
GOTERM_BP_ALL  RNA splicing  4 7.1E-3  1.2E-1 
GOTERM_BP_ALL  mRNA processing  4 1.0E-2  1.5E-1 
GOTERM_BP_ALL  mRNA metabolic process  4 1.5E-2  1.9E-1 
Annotation Cluster 5  Enrichment Score: 2.78  Count  P_Value  Benjamini 
GOTERM_CC_ALL  macromolecular complex  18 6.7E-10  1.7E-8 
GOTERM_MF_ALL  protein binding  20 3.9E-4  6.0E-3 
GOTERM_CC_ALL  intracellular part  20 3.4E-3  1.5E-2 
GOTERM_CC_ALL  intracellular  20 6.1E-3  2.5E-2 
GOTERM_MF_ALL  binding  21 1.0E-1  5.2E-1 
GOTERM_CC_ALL  cell part  21 2.4E-1  5.1E-1 
GOTERM_CC_ALL  cell  21 2.4E-1  5.0E-1 
Annotation Cluster 6  Enrichment Score: 2.76  Count  P_Value  Benjamini 
INTERPRO  Nucleotide-binding, alpha-beta plait  5 1.3E-4  8.0E-3 
SMART  RRM  4 1.8E-3  1.9E-2 
INTERPRO  RNA recognition motif, RNP-1  4 2.3E-3  6.6E-2 
UP_SEQ_FEATURE  domain:RRM 2  3 5.4E-3  4.0E-1 
UP_SEQ_FEATURE  domain:RRM 1  3 5.4E-3  4.0E-1 
Annotation Cluster 7  Enrichment Score: 2.34  Count  P_Value  Benjamini 
GOTERM_BP_ALL  RNA processing  7 8.0E-5  3.8E-3 
GOTERM_BP_ALL  ncRNA processing  3 2.8E-2  3.0E-1 
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GOTERM_BP_ALL  ncRNA metabolic process  3 4.1E-2  3.7E-1 
Annotation Cluster 8  Enrichment Score: 1.28  Count  P_Value  Benjamini 
GOTERM_BP_ALL  ribosome biogenesis  3 1.3E-2  1.8E-1 
GOTERM_BP_ALL  ribonucleoprotein complex biogenesis  3 2.6E-2  2.9E-1 
GOTERM_BP_ALL  cellular component biogenesis  3 4.2E-1  9.8E-1 
Annotation Cluster 9  Enrichment Score: 0.85  Count  P_Value  Benjamini 
GOTERM_CC_ALL  nuclear part  10 1.7E-4  9.7E-4 
GOTERM_CC_ALL  nucleolus  6 1.4E-3  6.6E-3 
GOTERM_MF_ALL  nucleotide binding  10 1.8E-3  2.3E-2 
GOTERM_CC_ALL  nuclear lumen  7 7.2E-3  2.6E-2 
SMART  AAA  3 1.3E-2  6.7E-2 
INTERPRO  ATPase, AAA+ type, core  3 1.4E-2  2.5E-1 
GOTERM_CC_ALL  intracellular organelle lumen  7 1.9E-2  6.2E-2 
UP_SEQ_FEATURE  nucleotide phosphate-binding region:ATP  5 1.9E-2  5.9E-1 
GOTERM_CC_ALL  organelle lumen  7 2.1E-2  6.6E-2 
GOTERM_CC_ALL  membrane-enclosed lumen  7 2.3E-2  6.9E-2 
SP_PIR_KEYWORDS  nucleus  10 2.8E-2  2.2E-1 
GOTERM_BP_ALL  DNA replication  3 2.9E-2  3.0E-1 
GOTERM_BP_ALL  nucleobase, nucleoside, nucleotide and nucleic acid 
metabolic process  
10 3.3E-2  3.2E-1 
GOTERM_BP_ALL  cellular nitrogen compound metabolic process  10 5.1E-2  4.3E-1 
SP_PIR_KEYWORDS  atp-binding  5 5.2E-2  3.1E-1 
GOTERM_BP_ALL  nitrogen compound metabolic process  10 6.1E-2  4.7E-1 
GOTERM_CC_ALL  nucleus  11 7.1E-2  1.9E-1 
GOTERM_MF_ALL  nucleoside-triphosphatase activity  4 7.7E-2  5.9E-1 
GOTERM_MF_ALL  pyrophosphatase activity  4 8.5E-2  5.7E-1 
GOTERM_MF_ALL  hydrolase activity, acting on acid anhydrides, in 
phosphorus-containing anhydrides  
4 8.6E-2  5.3E-1 
GOTERM_MF_ALL  hydrolase activity, acting on acid anhydrides  4 8.7E-2  5.0E-1 
GOTERM_CC_ALL  nucleoplasm  4 9.6E-2  2.5E-1 
SP_PIR_KEYWORDS  nucleotide-binding  5 1.1E-1  5.0E-1 
GOTERM_MF_ALL  ATP binding  5 1.4E-1  6.3E-1 
GOTERM_MF_ALL  adenyl ribonucleotide binding  5 1.5E-1  6.1E-1 
GOTERM_BP_ALL  DNA metabolic process  3 1.6E-1  8.1E-1 
GOTERM_MF_ALL  adenyl nucleotide binding  5 1.7E-1  6.4E-1 
GOTERM_MF_ALL  purine nucleoside binding  5 1.8E-1  6.3E-1 
GOTERM_MF_ALL  nucleoside binding  5 1.8E-1  6.1E-1 
GOTERM_BP_ALL  regulation of gene expression  7 2.0E-1  8.8E-1 
GOTERM_MF_ALL  ribonucleotide binding  5 2.5E-1  7.2E-1 
GOTERM_MF_ALL  purine ribonucleotide binding  5 2.5E-1  7.2E-1 
GOTERM_MF_ALL  purine nucleotide binding  5 2.7E-1  7.4E-1 
GOTERM_BP_ALL  cell cycle  3 3.0E-1  9.6E-1 
GOTERM_BP_ALL  regulation of macromolecule metabolic process  7 3.1E-1  9.6E-1 
GOTERM_BP_ALL  regulation of primary metabolic process  7 3.2E-1  9.6E-1 
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SP_PIR_KEYWORDS  dna-binding  4 3.3E-1  8.7E-1 
GOTERM_BP_ALL  regulation of cellular metabolic process  7 3.6E-1  9.8E-1 
GOTERM_BP_ALL  regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process  
6 3.7E-1  9.7E-1 
GOTERM_BP_ALL  regulation of nitrogen compound metabolic process  6 3.8E-1  9.7E-1 
GOTERM_BP_ALL  regulation of metabolic process  7 4.1E-1  9.8E-1 
GOTERM_CC_ALL  protein complex  5 4.1E-1  7.1E-1 
GOTERM_CC_ALL  intracellular membrane-bounded organelle  12 4.2E-1  7.0E-1 
GOTERM_CC_ALL  membrane-bounded organelle  12 4.2E-1  6.9E-1 
GOTERM_BP_ALL  transcription  4 5.9E-1  1.0E0 
GOTERM_BP_ALL  regulation of macromolecule biosynthetic process  5 5.9E-1  1.0E0 
GOTERM_BP_ALL  regulation of cellular biosynthetic process  5 6.3E-1  1.0E0 
GOTERM_BP_ALL  regulation of biosynthetic process  5 6.3E-1  1.0E0 
GOTERM_MF_ALL  hydrolase activity  4 6.3E-1  9.8E-1 
GOTERM_MF_ALL  DNA binding  4 6.5E-1  9.8E-1 
SP_PIR_KEYWORDS  transcription regulation  3 6.6E-1  9.9E-1 
SP_PIR_KEYWORDS  Transcription  3 6.8E-1  9.9E-1 
GOTERM_BP_ALL  regulation of transcription  4 7.4E-1  1.0E0 
GOTERM_BP_ALL  regulation of RNA metabolic process  3 7.5E-1  1.0E0 
GOTERM_MF_ALL  catalytic activity  7 7.8E-1  1.0E0 
GOTERM_BP_ALL  biological regulation  10 8.3E-1  1.0E0 
GOTERM_BP_ALL  regulation of cellular process  9 8.3E-1  1.0E0 
GOTERM_BP_ALL  regulation of biological process  9 8.8E-1  1.0E0 
SP_PIR_KEYWORDS  alternative splicing  6 9.5E-1  1.0E0 
UP_SEQ_FEATURE  splice variant  6 9.6E-1  1.0E0 
GOTERM_BP_ALL  response to stimulus  3 9.7E-1  1.0E0 
Annotation Cluster 10  Enrichment Score: 0.69  Count  P_Value  Benjamini 
GOTERM_CC_ALL  cytoskeletal part  4 1.1E-1  2.8E-1 
GOTERM_CC_ALL  microtubule cytoskeleton  3 1.5E-1  3.5E-1 
GOTERM_CC_ALL  cytoskeleton  4 2.5E-1  4.9E-1 
GOTERM_CC_ALL  protein complex  5 4.1E-1  7.1E-1 
Annotation Cluster 11  Enrichment Score: 0.12  Count  P_Value  Benjamini 
GOTERM_BP_ALL  anatomical structure morphogenesis  3 5.2E-1  9.9E-1 
GOTERM_BP_ALL  anatomical structure development  3 9.0E-1  1.0E0 
GOTERM_BP_ALL  developmental process  3 9.6E-1  1.0E0 
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Appendix 2: 11 proteins with the fold change of less than 0.5 were analyzed in DAVID database resulting in 10 
clusters. Count is representing number of proteins involved in the different processes in the cell or cellular part. 
P-value and Benjamini are the statistical measurements of significance where the lower number means higher 
significance. 
Proteins with fold change of less than 0.5    
11 DAVID IDs     
Annotation Cluster 1  Enrichment Score: 3.16  Count P_Value  Benjamini 
OMIM_DISEASE  Ullrich congenital muscular dystrophy  3 2.7E-6  2.4E-5 
OMIM_DISEASE  Bethlem myopathy  3 2.7E-6  2.4E-5 
PIR_SUPERFAMILY  PIRSF002259:collagen VI  3 3.9E-6  3.2E-5 
UP_SEQ_FEATURE  domain:VWFA 3  3 5.2E-6  5.8E-4 
SP_PIR_KEYWORDS  cell binding  3 2.5E-5  1.7E-3 
UP_SEQ_FEATURE  domain:VWFA 1  3 2.9E-5  1.6E-3 
GOTERM_CC_ALL  proteinaceous extracellular matrix  5 3.1E-5  2.2E-3 
UP_SEQ_FEATURE  domain:VWFA 2  3 3.3E-5  1.2E-3 
GOTERM_CC_ALL  extracellular matrix  5 4.1E-5  1.5E-3 
UP_SEQ_FEATURE  region of interest:Triple-helical region  3 6.2E-5  1.7E-3 
SP_PIR_KEYWORDS  trimer  3 7.9E-5  2.6E-3 
SP_PIR_KEYWORDS  hydroxylysine  3 1.1E-4  2.5E-3 
SP_PIR_KEYWORDS  triple helix  3 1.1E-4  2.5E-3 
SP_PIR_KEYWORDS  hydroxyproline  3 1.6E-4  2.7E-3 
SP_PIR_KEYWORDS  extracellular matrix  4 2.2E-4  2.9E-3 
SP_PIR_KEYWORDS  pyroglutamic acid  3 2.5E-4  2.8E-3 
SP_PIR_KEYWORDS  hydroxylation  3 5.9E-4  5.0E-3 
GOTERM_CC_ALL  sarcolemma  3 7.7E-4  1.9E-2 
SP_PIR_KEYWORDS  Secreted  6 9.0E-4  6.7E-3 
UP_SEQ_FEATURE  short sequence motif:Cell attachment site  3 9.2E-4  1.5E-2 
INTERPRO  von Willebrand factor, type A  3 9.7E-4  3.6E-2 
SP_PIR_KEYWORDS  blocked amino end  3 9.9E-4  6.6E-3 
SP_PIR_KEYWORDS  collagen  3 1.1E-3  6.4E-3 
INTERPRO  Collagen triple helix repeat  3 1.1E-3  2.1E-2 
SMART  VWA  3 1.5E-3  1.5E-2 
GOTERM_CC_ALL  extracellular region part  5 2.1E-3  2.5E-2 
KEGG_PATHWAY  ECM-receptor interaction  3 3.9E-3  4.9E-2 
GOTERM_CC_ALL  extracellular region  6 4.7E-3  4.8E-2 
UP_SEQ_FEATURE  glycosylation site:N-linked (GlcNAc...)  7 9.5E-3  1.2E-1 
SP_PIR_KEYWORDS  glycoprotein  7 1.1E-2  5.8E-2 
SP_PIR_KEYWORDS  cell adhesion  3 1.9E-2  8.9E-2 
KEGG_PATHWAY  Focal adhesion  3 2.1E-2  1.3E-1 
SP_PIR_KEYWORDS  disease mutation  4 4.4E-2  1.8E-1 
GOTERM_BP_ALL  cell adhesion  3 5.6E-2  1.0E0 
GOTERM_BP_ALL  biological adhesion  3 5.6E-2  9.9E-1 
GOTERM_CC_ALL  extracellular space  3 6.6E-2  2.8E-1 
SP_PIR_KEYWORDS  coiled coil  4 7.9E-2  2.9E-1 
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GOTERM_CC_ALL  plasma membrane  4 4.4E-1  8.0E-1 
Annotation Cluster 2  Enrichment Score: 2.03  Count P_Value  Benjamini 
SP_PIR_KEYWORDS  signal  8 2.9E-4  2.8E-3 
UP_SEQ_FEATURE  signal peptide  8 3.0E-4  6.8E-3 
SP_PIR_KEYWORDS  Secreted  6 9.0E-4  6.7E-3 
GOTERM_CC_ALL  extracellular region  6 4.7E-3  4.8E-2 
SP_PIR_KEYWORDS  polymorphism  9 1.7E-1  5.2E-1 
UP_SEQ_FEATURE  sequence variant  9 2.2E-1  9.3E-1 
GOTERM_MF_ALL  binding  10 4.6E-1  1.0E0 
Annotation Cluster 3  Enrichment Score: 1.6  Count P_Value  Benjamini 
UP_SEQ_FEATURE  short sequence motif:Prevents secretion from ER  3 4.1E-4  7.7E-3 
GOTERM_CC_ALL  endoplasmic reticulum lumen  3 1.1E-3  2.0E-2 
GOTERM_CC_ALL  pigment granule  3 1.4E-3  2.0E-2 
GOTERM_CC_ALL  melanosome  3 1.4E-3  2.0E-2 
SP_PIR_KEYWORDS  endoplasmic reticulum  4 5.0E-3  2.8E-2 
GOTERM_CC_ALL  endoplasmic reticulum part  3 1.9E-2  1.6E-1 
GOTERM_CC_ALL  endoplasmic reticulum  4 1.9E-2  1.4E-1 
GOTERM_CC_ALL  cytoplasmic membrane-bounded vesicle  3 4.5E-2  2.8E-1 
GOTERM_CC_ALL  membrane-bounded vesicle  3 4.7E-2  2.8E-1 
GOTERM_CC_ALL  cytoplasmic vesicle  3 5.9E-2  2.9E-1 
GOTERM_CC_ALL  vesicle  3 6.4E-2  2.9E-1 
GOTERM_CC_ALL  intracellular organelle part  5 2.6E-1  7.1E-1 
GOTERM_CC_ALL  organelle part  5 2.7E-1  6.9E-1 
GOTERM_CC_ALL  intracellular organelle lumen  3 3.1E-1  7.2E-1 
GOTERM_CC_ALL  organelle lumen  3 3.2E-1  7.2E-1 
GOTERM_CC_ALL  membrane-enclosed lumen  3 3.3E-1  7.2E-1 
Annotation Cluster 4  Enrichment Score: 1  Count P_Value  Benjamini 
GOTERM_MF_ALL  endopeptidase activity  3 2.4E-2  8.7E-1 
GOTERM_MF_ALL  peptidase activity, acting on L-amino acid 
peptides  
3 4.9E-2  8.8E-1 
GOTERM_MF_ALL  peptidase activity  3 5.3E-2  7.8E-1 
GOTERM_MF_ALL  hydrolase activity  4 1.8E-1  9.7E-1 
SP_PIR_KEYWORDS  hydrolase  3 1.9E-1  5.3E-1 
GOTERM_MF_ALL  catalytic activity  5 4.7E-1  1.0E0 
Annotation Cluster 5  Enrichment Score: 0.85  Count P_Value  Benjamini 
GOTERM_CC_ALL  extracellular space  3 6.6E-2  2.8E-1 
UP_SEQ_FEATURE  disulfide bond  4 1.7E-1  9.1E-1 
GOTERM_MF_ALL  hydrolase activity  4 1.8E-1  9.7E-1 
SP_PIR_KEYWORDS  disulfide bond  4 1.9E-1  5.3E-1 
Annotation Cluster 6  Enrichment Score: 0.49  Count P_Value  Benjamini 
GOTERM_CC_ALL  cytoplasmic part  7 5.3E-2  2.8E-1 
GOTERM_CC_ALL  organelle membrane  3 1.5E-1  5.0E-1 
GOTERM_CC_ALL  intracellular organelle part  5 2.6E-1  7.1E-1 
GOTERM_CC_ALL  organelle part  5 2.7E-1  6.9E-1 
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GOTERM_CC_ALL  cytoplasm  7 2.8E-1  7.0E-1 
GOTERM_CC_ALL  intracellular membrane-bounded organelle  7 3.8E-1  7.7E-1 
GOTERM_CC_ALL  membrane-bounded organelle  7 3.8E-1  7.6E-1 
GOTERM_CC_ALL  intracellular organelle  7 5.4E-1  8.8E-1 
GOTERM_CC_ALL  organelle  7 5.4E-1  8.7E-1 
GOTERM_CC_ALL  intracellular part  7 7.9E-1  9.8E-1 
GOTERM_CC_ALL  intracellular  7 8.3E-1  9.9E-1 
Annotation Cluster 7  Enrichment Score: 0.36  Count P_Value  Benjamini 
GOTERM_MF_ALL  calcium ion binding  3 1.2E-1  9.3E-1 
GOTERM_MF_ALL  cation binding  4 5.5E-1  1.0E0 
SP_PIR_KEYWORDS  phosphoprotein  5 5.6E-1  9.3E-1 
GOTERM_MF_ALL  ion binding  4 5.6E-1  1.0E0 
GOTERM_MF_ALL  metal ion binding  3 8.0E-1  1.0E0 
Annotation Cluster 8  Enrichment Score: 0.24  Count P_Value  Benjamini 
GOTERM_CC_ALL  intracellular organelle part  5 2.6E-1  7.1E-1 
GOTERM_CC_ALL  organelle part  5 2.7E-1  6.9E-1 
GOTERM_BP_ALL  regulation of cellular process  3 9.6E-1  1.0E0 
GOTERM_BP_ALL  regulation of biological process  3 9.7E-1  1.0E0 
GOTERM_BP_ALL  biological regulation  3 9.8E-1  1.0E0 
Annotation Cluster 9  Enrichment Score: 0.05  Count P_Value  Benjamini 
GOTERM_CC_ALL  membrane part  4 8.5E-1  9.9E-1 
GOTERM_CC_ALL  integral to membrane  3 9.0E-1  9.9E-1 
GOTERM_CC_ALL  intrinsic to membrane  3 9.1E-1  9.9E-1 
Annotation Cluster 10  Enrichment Score: 0.04  Count P_Value  Benjamini 
GOTERM_BP_ALL  macromolecule metabolic process  3 9.0E-1  1.0E0 
GOTERM_BP_ALL  metabolic process  4 9.0E-1  1.0E0 
GOTERM_BP_ALL  primary metabolic process  3 9.6E-1  1.0E0 
 
 
 
